The complotype: Dictating risk for inflammation and infection

Trends in Immunology

Volumn 33, Issue 10, 2012, Pages 513-521

  Harris, Claire L ^a   Heurich, Meike ^a   Cordoba, Santiago Rodriguez de ^b   Morgan, B Paul ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Alternative pathway; Complement; Complotype; Inflammation

Indexed keywords

COMPLEMENT;

COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DISEASE PREDISPOSITION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; INFECTION; INFECTION RISK; INFLAMMATION; REVIEW;

ANIMALS; GENOTYPE; HUMANS; INFECTION; INFLAMMATION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 84866753225     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2012.06.001     Document Type: Review

References (79)

1. Ricklin D., et al. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
2. Lachmann P.J. The amplification loop of the complement pathways. Adv. Immunol. 2009, 104:115-149.
3. Pangburn M.K., et al. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J. Exp. Med. 1981, 154:856-867.
4. Fearon D.T. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc. Natl. Acad. Sci. U.S.A. 1978, 75:1971-1975.
5. Jozsi M., Zipfel P.F. Factor H family proteins and human diseases. Trends Immunol. 2008, 29:380-387.
6. Fritsche L.G., et al. An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum. Mol. Genet. 2010, 19:4694-4704.
7. Morgan B.P., Meri S. Membrane proteins that protect against complement lysis. Springer Semin. Immunopathol. 1994, 15:369-396.
8. Complement Regulatory Proteins 1999, Academic Press. B.P. Morgan, C.L. Harris (Eds.).
9. Lotery A., et al. Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study. Br. J. Ophthalmol. 2007, 91:1303-1307.
10. Haines J.L., et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005, 308:419-421.
11. Edwards A.O., et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005, 308:421-424.
12. Klein R.J., et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005, 308:385-389.
13. Hageman G.S., et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:7227-7232.
14. Hughes A.E., et al. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat. Genet. 2006, 38:1173-1177.
15. Abarrategui-Garrido C., et al. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009, 114:4261-4271.
16. Martinez-Barricarte R., et al. Relevance of complement factor H-related 1 (CFHR1) genotypes in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2012, 53:1087-1094.
17. Gold B., et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat. Genet. 2006, 38:458-462.
18. Yates J.R., et al. Complement C3 variant and the risk of age-related macular degeneration. N. Engl. J. Med. 2007, 357:553-561.
19. Fagerness J.A., et al. Variation near complement factor I is associated with risk of advanced AMD. Eur. J. Hum. Genet. 2009, 17:100-104.
20. Pickering M.C., Cook H.T. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin. Exp. Immunol. 2008, 151:210-230.
21. Pickering M.C., et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J. Exp. Med. 2007, 204:1249-1256.
22. Abrera-Abeleda M.A., et al. Allelic variants of complement genes associated with dense deposit disease. J. Am. Soc. Nephrol. 2011, 22:1551-1559.
23. Caprioli J., et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum. Mol. Genet. 2003, 12:3385-3395.
24. Esparza-Gordillo J., et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum. Mol. Genet. 2005, 14:703-712.
25. Manuelian T., et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J. Clin. Invest. 2003, 111:1181-1190.
26. Rodriguez de Cordoba S., Goicoechea de Jorge E. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin. Exp. Immunol. 2008, 151:1-13.
27. Goicoechea de Jorge E., et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:240-245.
28. Fremeaux-Bacchi V., et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008, 112:4948-4952.
29. Rodriguez de Cordoba S., et al. Lessons from functional and structural analyses of disease-associated genetic variants in the complement alternative pathway. Biochim. Biophys. Acta 2011, 1812:12-22.
30. Martinez-Barricarte R., et al. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 2008, 19:639-646.
31. Scholl H.P., et al. Systemic complement activation in age-related macular degeneration. PLoS ONE 2008, 3:e2593.
32. Reynolds R., et al. Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest. Ophthalmol. Vis. Sci. 2009, 50:5818-5827.
33. Hecker L.A., et al. Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum. Mol. Genet. 2010, 19:209-215.
34. Montes T., et al. Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:4366-4371.
35. Tortajada A., et al. The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Hum. Mol. Genet. 2009, 18:3452-3461.
36. Pechtl I.C., et al. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J. Biol. Chem. 2011, 286:11082-11090.
37. Heurich M., et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:8761-8766.
38. Sjoberg A.P., et al. The factor H variant associated with age-related macular degeneration (His-384) and the non-disease-associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells. J. Biol. Chem. 2007, 282:10894-10900.
39. Mihlan M., et al. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ. 2009, 16:1630-1640.
40. Clark S.J., et al. His-384 allotypic variant of factor H associated with age-related macular degeneration has different heparin binding properties from the non-disease-associated form. J. Biol. Chem. 2006, 281:24713-24720.
41. Herbert A.P., et al. Structure shows that a glycosaminoglycan and protein recognition site in factor H is perturbed by age-related macular degeneration-linked single nucleotide polymorphism. J. Biol. Chem. 2007, 282:18960-18968.
42. Prosser B.E., et al. Structural basis for complement factor H linked age-related macular degeneration. J. Exp. Med. 2007, 204:2277-2283.
43. Clark S.J., et al. Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Bruch's membrane in human retina. J. Biol. Chem. 2010, 285:30192-30202.
44. Weismann D., et al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 2011, 478:76-81.
45. Alper C.A., et al. Complement genes of the major histocompatibility complex (complotypes), extended haplotypes and disease markers. Biochem. Soc. Symp. 1986, 51:19-28.
46. Kardys I., et al. A common polymorphism in the complement factor H gene is associated with increased risk of myocardial infarction: the Rotterdam Study. J. Am. Coll. Cardiol. 2006, 47:1568-1575.
47. Messias-Reason I.J., et al. Complement C3 F and BF S allotypes are risk factors for Chagas disease cardiomyopathy. Tissue Antigens 2003, 62:308-312.
48. Papiha S.S., et al. Factor B (BF) allotypes and multiple sclerosis in north-east England. Hum. Hered. 1991, 41:397-402.
49. Hagglof B., et al. Studies of HLA, factor B (Bf), complement C2 and C4 haplotypes in type 1 diabetic and control families from northern Sweden. Hum. Hered. 1986, 36:201-212.
50. Finn J.E., Mathieson P.W. Molecular analysis of C3 allotypes in patients with nephritic factor. Clin. Exp. Immunol. 1993, 91:410-414.
51. Andrews P.A., et al. Molecular analysis of C3 allotypes related to transplant outcome in human renal allografts. Transplantation 1995, 60:1342-1346.
52. Rambausek M., et al. Genetic polymorphism of C3 and Bf in IgA nephropathy. Nephrol. Dial. Transplant. 1987, 2:208-211.
53. Finn J.E., et al. Molecular analysis of C3 allotypes in patients with systemic vasculitis. Nephrol. Dial. Transplant. 1994, 9:1564-1567.
54. Harold D., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41:1088-1093.
55. Lambert J.C., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41:1094-1099.
56. Fearon D.T., Carter R.H. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu. Rev. Immunol. 1995, 13:127-149.
57. Ahearn J.M., Fearon D.T. Structure and function of the complement receptors CR1 (CD35) and CR2 (CD21). Adv. Immunol. 1989, 46:183-219.
58. Keenan B.T., et al. A coding variant in CR1 interacts with APOE-{varepsilon}4 to influence cognitive decline. Hum. Mol. Genet. 2012, 21:2377-2388.
59. Thambisetty M., et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch. Gen. Psychiatry 2010, 67:739-748.
60. Szymanski M., et al. Alzheimer's risk variants in the Clusterin gene are associated with alternative splicing. Transl. Psychiatry 2011, 1:e18.
61. Xing Y.Y., et al. Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer's disease. J. Alzheimers Dis. 2012, 29:515-519.
62. Kurreeman F.A., et al. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis. PLoS Med. 2007, 4:e278.
63. Zhernakova A., et al. Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet. 2011, 7:e1002004.
64. Morgan B.P., et al. Measurement of terminal complement complexes in rheumatoid arthritis. Clin. Exp. Immunol. 1988, 73:473-478.
65. Wang Q., et al. Identification of a central role for complement in osteoarthritis. Nat. Med. 2011, 17:1674-1679.
66. Jeong J.C., et al. Association of complement 5 genetic polymorphism with renal allograft outcomes in Korea. Nephrol. Dial. Transplant. 2011, 26:3378-3385.
67. Song J.J., et al. Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J. Clin. Invest. 2011, 121:3517-3527.
68. Nishiguchi K.M., et al. C9-R95X polymorphism in patients with neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2012, 53:508-512.
69. Ermini L., et al. Complement polymorphisms: geographical distribution and relevance to disease. Immunobiology 2011, 217:265-271.
70. de Vries R.R., et al. Genetic control of survival in epidemics. J. Immunogenet. 1979, 6:271-287.
71. Davila S., et al. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat. Genet. 2010, 42:772-776.
72. Harrison L.H., et al. Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl. 2):B51-B63.
73. Haralambous E., et al. Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand. J. Infect. Dis. 2006, 38:764-771.
74. Madico G., et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 2006, 177:501-510.
75. Woehrl B., et al. Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. J. Clin. Invest. 2011, 121:3943-3953.
76. Hakobyan S., et al. Variant-specific quantification of factor H in plasma identifies null alleles associated with atypical hemolytic uremic syndrome. Kidney Int. 2010, 78:782-788.
77. Wieme R.J., Demeulenaere L. Genetically determined electrophoretic variant of the human complement component C'3. Nature 1967, 214:1042-1043.
78. Alper C.A., et al. Genetic polymorphism in human glycine-rich beta-glycoprotein. J. Exp. Med. 1972, 135:68-80.
79. Rodriguez de Cordoba S., Rubinstein P. Genetic polymorphism of human factor H (beta 1H). J. Immunol. 1984, 132:1906-1908.